SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

The researchers found that individual SGLT-2 inhibitors showed similar cardiovascular effectiveness at clinically effective ...

New research shows diabetes medication SGLT-2 inhibitors lower dementia risk by up to 35%, offering hope for millions ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor ...

China: Combining dapagliflozin with calorie restriction resulted in a higher rate of type 2 diabetes (T2D) remission, along ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 ...

Combined strategy is effective but questions remain The view that the hyperglycaemia associated with type 2 diabetes is ...

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.